Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 10,533 matching trials from the local directory fallback.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 1 Interventional

Regulatory T Cells for Amyotrophic Lateral Sclerosis

NCT05695521
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK0803, Excipient
Biological · Other
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 12:59 PM EDT
Active, not recruiting Not applicable Interventional

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

NCT05591066
View directory record Official record
Conditions
Communication
Interventions
PFC I-PASS+ Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
14,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 7:09 PM EDT
Active, not recruiting Not applicable Interventional

AWV Practice Redesign Toolkit (Tailored Intervention)

NCT05563415
View directory record Official record
Conditions
Preventive Health Services
Interventions
Medicare AWV Practice Redesign Toolkit
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
13,321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 9:59 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)

NCT05375162
View directory record Official record
Conditions
Cancer
Interventions
Buddy, Core Intervention, E-Coach, General Mindfulness Training, MVPA-Specific Mindfulness Training
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 39 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 12:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Implementing PrEP for Women Who Inject Drugs

NCT05360849
View directory record Official record
Conditions
HIV, Implementation Science, Intravenous Substance Abuse, Organization and Administration, Primary Prevention, Women's Health
Interventions
Practice Facilitation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 12:58 PM EDT
Active, not recruiting Not applicable Interventional

The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients

NCT05226078
View directory record Official record
Conditions
Cancer-Related Syndrome, Cancer-related Problem/Condition, Chronic Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 8:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

NCT05141682
View directory record Official record
Conditions
T-Cell Large Granular Lymphocyte Leukemia
Interventions
Oral Azacitidine
Drug
Lead sponsor
Jonathan Brammer
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
View directory record Official record
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 2:16 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Pembrolizumab, Pemetrexed, Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 123 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 6, 2026, 3:30 PM EST
Active, not recruiting Phase 3 Interventional

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090
View directory record Official record
Conditions
Papillary Renal Cell Carcinoma
Interventions
durvalumab, savolitinib, sunitinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 9:34 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens

NCT04946084
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Blood Draw, Nasal Phalangeal Swab and Wash, Tympanocentesis
Other · Procedure
Lead sponsor
Rochester General Hospital
Other
Eligibility
6 Months to 36 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 7:07 PM EDT
Active, not recruiting No phase listed Observational

CareCOPD - COPD Home Monitoring Study

NCT04918095
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CareCOPD Platform
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 4:30 PM EDT
Active, not recruiting Not applicable Interventional

Manage Emotions to Reduce Aggression (MERA)

NCT04793776
View directory record Official record
Conditions
Aggression, Emotion Regulation, Stress Disorders, Post-Traumatic
Interventions
Manage Emotions to Reduce Aggression, Present Centered Psychotherapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04781088
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Lenvatinib, Paclitaxel, Pembrolizumab
Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 6:15 AM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib in High Grade Neuroendocrine Neoplasms

NCT04412629
View directory record Official record
Conditions
High Grade Neuroendocrine Neoplasms
Interventions
Blood for plasma biomarkers, Cabozantinib, Tissue biopsy
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

NCT04404894
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
7
States / cities
Homewood, Alabama • Long Beach, California • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 12:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Brentuximab vedotin, Lenalidomide, Placebo, Rituximab
Drug · Other
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 3:21 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04367675
View directory record Official record
Conditions
BRCA1/2 Mutation
Interventions
Cellectra 2000, INO-5401, INO-9012
Device · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 12:48 AM EDT
Active, not recruiting Phase 1 Interventional

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

NCT03773393
View directory record Official record
Conditions
Bone Marrow Disease
Interventions
CK0801
Biological
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 12:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

NCT03728972
View directory record Official record
Conditions
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Interventions
Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Stanford, California • Basking Ridge, New Jersey • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:32 PM EDT
Active, not recruiting Not applicable Interventional Results available

Baby's First Years

NCT03593356
View directory record Official record
Conditions
Brain Development, Child Development, Household and Family Processes
Interventions
Monthly cash gift payments of $20, Monthly cash gift payments of $333
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:40 PM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 3:13 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injectable Suspension, Cabotegravir Tablets, Rilpivirine Injectable Suspension, Rilpivirine Tablets
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 9:03 PM EST
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

NCT03279692
View directory record Official record
Conditions
High Grade Meningioma
Interventions
Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:43 PM EDT